NCT06807502 Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device
| NCT ID | NCT06807502 |
| Status | Recruiting |
| Phase | — |
| Sponsor | ScreenCell |
| Condition | Breast Cancer, Metastatic |
| Study Type | INTERVENTIONAL |
| Enrollment | 93 participants |
| Start Date | 2025-02-24 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 93 participants in total. It began in 2025-02-24 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up. The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up
Eligibility Criteria
INCLUSION CRITERIA For all participants : * Female with age greater than or equal to 18 years For participants with metastatic breast cancer: \- Patient observed with metastatic breast cancer from the outset or metastatic fall from previously treated breast cancer with change of therapeutic line at the time of inclusion. For participants with non-metastatic invasive breast cancer: \- Patient observed with non-metastatic infiltrative breast cancer who had not received any treatment at the time of inclusion (naïve to any treatment) For healthy volunteers: * Participant free of any cancer at the time of inclusion, confirmed using a mammogram whose results must be satisfactory, done at the latest two years before inclusion * Participant with no history of cancer EXCLUSION CRITERIA For all participants: * Male * Age less than 18 years old * Refusal to participate or withdrawal of consent * Pregnant and/or breastfeeding women * Discovery of a cancerous pathology (other than breast cancer for patients) during participant follow-up. For healthy volunteers: * History of cancer * Detection of CTC (positive profile) during screening
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06807502 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer, Metastatic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06807502 currently recruiting?
Yes, NCT06807502 is actively recruiting participants. Contact the research team at jgroult@screencell.com for enrollment information.
Where is the NCT06807502 trial being conducted?
This trial is being conducted at Neuilly-sur-Seine, France.
Who is sponsoring the NCT06807502 clinical trial?
NCT06807502 is sponsored by ScreenCell. The trial plans to enroll 93 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.